BIAF
bioAffinity Technologies, Inc. Common StockRecent alerts on BIAF
All signals →
SEC filing
BIAF Reports $0 Revenue, $0 EPS, Announces CyPath Lung Webinar with 92% Sensitivity, 87% Specificity
6h ago
SEC filing
BIAF Announces Mexican Patent Allowance for CyPath Lung, Expanding Global IP Portfolio, 92% Sensitivity, 87% Specificity
6d ago
News
bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M
25d ago
SEC filing
BIAF Reports $1.4M Revenue, CyPath Lung Sales Up 146% YoY to $361K, Physician Adoption Rises 69%
25d ago
SEC filing
BIAF Reports 92% Sensitivity, 87% Specificity for CyPath® Lung in Lung Cancer Detection, Supports Deferral of Invasive Biopsy
49d ago
SEC filing
BIAF Hosts Live Virtual Physician Roundtable on CyPath® Lung Integration, 92% Sensitivity, 87% Specificity, April 8, 2026, 7 p.m. ET
68d ago
SEC filing
BIAF Launches 2,000-Patient CyPath Lung Longitudinal Study, 92% Sensitivity, 87% Specificity, 20 Sites Including VA Hospitals, NCT07168993
84d ago
SEC filing
BIAF Announces Board Exit of Robert Anderson and Roby Joyce Ahead of April 30 Annual Meeting
87d ago
News
Biotech Startup M&A Is Reliably Delivering Some Big Exits - Crunchbase News
104d ago
News
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - Nasdaq
108d ago
News
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
108d ago
News
Hair Loss Biopharma Firm Veradermics Raises $256 Million in IPO
118d ago
Scanner
Unusual volume (3.6x average)
124d ago
Get push alerts for BIAF
Add it to your watchlist in the app and receive every signal the moment it fires.
Download for iOS